Physician profile
Alexander Wainwright
NPI 1811230824
$1,914.65
in general payments reported to CMS, 2019-2025
22 companies · $459 in 2025
The $459 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $247 · 2023: $648 · 2024: $415 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $327.91 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $290.45 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $267.43 | 2022-2025 | |
| Astellas Pharma US INC | $136.95 | 2022-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $131.79 | 2023-2024 | Accrufer |
| Abbvie INC. | $112.09 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $107.84 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $82.04 | 2021-2025 | |
| Applied Medical Resources Corporation | $72.48 | 2021 | |
| Myovant Sciences INC. | $51.10 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $47.10 | 2025 | Exparel |
| Avion Pharmaceuticals | $38.64 | 2023 | Balcoltra |
| Hologic Sales and Service, LLC | $38.52 | 2024 | Acessa Provu System |
| Exeltis, USA INC. | $34.78 | 2024-2025 | Slynd |
| Innovation Technologies INC | $28.81 | 2024 | Irrisept |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.01 | 2025 | Vpriv |
| Dexcom, INC. | $25.50 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $23.79 | 2023 | Nexplanon |
| Smith+Nephew, INC. | $22.63 | 2023 | Oasis Micro |
| Millicent US INC | $18.90 | 2024 | Intrarosa, Femring |
| Abbott Laboratories | $17.22 | 2022 | |
| Medtronic, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Wainwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.